The FDA on March 18, 2022, approved OPDUALAG® for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG® is a fixed-dose combination of the LAG-3-blocking antibody Relatlimab and the Programmed Death receptor-1 blocking antibody, Nivolumab. OPDUALAG® is a product of Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
